

Supplementary Table 7: IBD-related HCRU and costs in UC patients with 2L advanced treatment, up to 6 years of follow-up, pairwise comparison with IFX as reference after IPW adjustment.

Health economic outcome parameters PPY	ADA (n=79) vs. IFX ¹	p-value ²	GOL (n=72) vs. IFX ¹	p-value ²	UST (n=80) vs. IFX ¹	p-value ²	VDZ (n=80) vs. IFX ¹	p-value ²
Number of IBD-related hospitalizations (events)	0.17 (0.74) vs. 0.26 (0.67)	0.2	0.13 (0.54) vs. 0.23 (0.65)	0.2	0.30 (1.20) vs. 0.23 (0.67)	0.7	0.19 (0.77) vs. 0.24 (0.69)	0.4
Duration of IBD-related hospital stays (days)	1.69 (9.10) vs. 4.27 (19.16)	0.2	1.76 (10.75) vs. 3.38 (15.94)	0.4	2.07 (8.24) vs. 3.34 (16.04)	0.5	2.91 (18.96) vs. 3.75 (17.75)	0.7
Number of IBD-related surgeries (events)	0.08 (0.41) vs. 0.39 (1.33)	0.035	0.13 (0.94) vs. 0.32 (1.15)	0.2	0.30 (0.79) vs. 0.34 (1.15)	0.9	0.20 (0.86) vs. 0.37 (1.28)	0.2
Duration of IBD-related sick-leave (days)	12 (31) vs. 26 (56)	0.087	18 (48) vs. 25 (51)	0.4	20 (70) vs. 25 (52)	0.8	27 (62) vs. 25 (57)	0.9
Number of IBD-related sick-leave (events)	0.59 (0.85) vs. 1.51 (2.15)	0.005	0.59 (0.92) vs. 1.55 (2.16)	0.006	0.69 (1.02) vs. 1.65 (2.25)	0.020	1.53 (2.13) vs. 1.61 (2.26)	0.8
Costs for IBD-specific hospitalizations (EUR)	686 (4,275) vs. 4,333 (28,572)	0.2	736 (4,507) vs. 3,067 (22,445)	0.2	4,171 (18,598) vs. 3,043 (22,092)	0.7	1,104 (5,799) vs. 3,720 (25,883)	0.3
Costs for IBD-specific medication (EUR)	19,874 (11,930) vs. 26,488 (16,499)	0.006	19,123 (9,272) vs. 26,967 (16,525)	<0.001	44,462 (33,262) vs. 27,011 (15,888)	<0.001	22,643 (9,374) vs. 26,698 (17,097)	0.036
Costs for IBD-specific out-patient treatment (EUR)	781 (526) vs. 1,261 (672)	<0.001	731 (445) vs. 1,285 (673)	<0.001	976 (714) vs. 1,303 (679)	0.049	1,012 (498) vs. 1,256 (688)	0.028
Total costs for IBD-specific treatment (EUR)	21,349 (12,627) vs. 32,147 (30,977)	0.005	20,601 (10,248) vs. 31,378 (26,338)	<0.001	49,660 (36,845) vs. 31,418 (25,648)	<0.001	24,793 (11,062) vs. 31,730 (29,247)	0.028
Total costs for all-cause treatment (EUR)	37,517 (30,009) vs. 38,902 (53,685)	0.8	36,281 (18,562) vs. 37,847 (50,852)	0.8	85,392 (105,512) vs. 38,147 (48,305)	<0.001	33,996 (29,609) vs. 38,648 (54,118)	0.4

ADA= Adalimumab IBD = Inflammatory bowel disease IFX = Infliximab IPW = inverse probability weighting HCRU = Healthcare resource utilization PPY = Per Patient Year UC = ulcerative colitis UST= Ustekinumab VDZ= Vedolizumab

¹Mean (SD), in 2L ADA/GOL/VDZ/UST vs. 2L IFX in UC patients

²Regression least-squares mean differences